OVERVIEW

Pancreas Symposium 2021: Personalizing Pancreas Care is organized by Columbia University Irving Medical Center (CUIMC) and will be held on Jun 17, 2021.

Target Audience:
This activity is designed for gastroenterologists, surgeons, internists, oncologists, radiologists, pathologists, RNs, PAs, NPs and other medical professionals involved in the evaluation, diagnosis and/or management of patients with benign and malignant pancreatic disease.

Accreditation:
Physicians:
Amedco LLC designates this live activity for a maximum of 4.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants:
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credits™ from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of 4.75 AMA PRA Category 1 Credits™ for completing this activity.

Program Overview:
Pancreas cancer, including patients at risk, as well as pancreatitis are among the most complex cases that physicians are confronted with as internists, gastroenterologists, oncologists, and surgeons. The Pancreas Symposium 2021 program will review cutting-edge diagnostics and treatments as well as those on the horizon for pancreas diseases, both benign and malignant. This year’s program will feature renowned experts in pancreas cancer care, diagnostics and pancreatitis. Our internationally recognized faculty will present lectures and case presentations to help practicing clinicians treat pancreatic disease.

Learning Objectives:
• Discuss chronic pancreatitis, including genetic risk factors and novel treatments, including endoscopic therapies and surgery
• Define standard of care treatment algorithms for pancreatic adenocarcinoma, including surgery, chemotherapy and radiation therapy
• Identify “new horizons” for improving survival in pancreatic adenocarcinoma, including when to consider clinical trials and immunotherapy, and when to recommend aggressive surgery
• Identify novel therapies for pancreatic ductal adenocarcinoma
• Describe the myriad of treatment guidelines for pancreas cystic neoplasms, as well as, explore diagnostic information on the horizon to further stratify risk and guide treatment
• Explain the role of genetics in pancreatic disease, both benign and malignant